HEPA | Hepion Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4801 - 0.5300
52 Week Range	0.4780 - 3.72
Beta	1.35
Implied Volatility	499.07%
IV Rank	27.69%
Day's Volume	48,091
Average Volume	43,879
Shares Outstanding	6,958,370
Market Cap	3,409,601
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-02-10

Valuation
Profitability
Growth
Health
P/E Ratio	-0.11
Forward P/E Ratio	N/A
EPS	-4.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	22
Country	USA
Website	HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

HEPA's peers: ABCL, ABSI, ACAD, ACHV, ADPT, AFMD, AKBA, ALT, ANNX, ARDX, AUPH, AVIR, AXSM, BCTX, BLUE, BNTX, BTAI, CELU, CNSP, CPRX, CRSP, DNA, DRMA, ELEV, ENVB, ETNB, FGEN, GALT, GERN, GNPX, CWBR, OCEA, AVRO, ZURA, EFTR, IMMX, INO, IOVA, LPCN, LPTX, LXRX, MDGL, MREO, MRNA, NBTX, NVO, OCGN, ORMP, PBYI, PHAT, PTCT, RCUS, RXRX, SRPT, TGTX, VKTX, XERS, XFOR, SPRY, ZVSA, CARM

*Chart delayed

Analyzing fundamentals for HEPA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see HEPA Fundamentals page.

Watching at HEPA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HEPA Technicals page.